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It has been reported that cellular prion protein (PrPc) is enriched in caveolae or caveolae-like domains with caveolin-1 (Cav-1)
participating to signal transduction events by Fyn kinase recruitment. By using the Glutathione-S-transferase (GST)-fusion pro-
teins assay, we observed that PrPc strongly interacts in vitro with Cav-1. Thus, we ascertained the PrPc caveolar localization in a
hypothalamic neuronal cell line (GN11), by confocal microscopy analysis, flotation on density gradient, and coimmunoprecipita-
tion experiments. Following the anti-PrPc antibody-mediated stimulation of live GN11 cells, we observed that PrPc clustered on
plasma membrane domains rich in Cav-1 in which Fyn kinase converged to be activated. After these events, a signaling cascade
through p42/44 MAP kinase (Erk 1/2) was triggered, suggesting that following translocations from rafts to caveolae or caveolae-
like domains PrPc could interact with Cav-1 and induce signal transduction events.
Copyright © 2006 Mattia Toni et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Multiproteic caveolar complexes represent a sophisticated
membrane organization involved in signal transduction.
Their efficiency is linked to the insertion of proteins in a
restricted membrane area (50–100 nm) where the genera-
tion of a signal has a vectorial and oriented characteristic
and allows the recruitment of low-abundance proteins in
order to activate signaling pathways which, in neural cells,
seem to control differentiation and cell survival [1–4]. Cave-
olae are a subclass of membrane microdomains distinguish-
able by their shape (they are flask-like invaginations) and by
the presence of membrane proteins of the caveolin family.
Caveolin-1 (Cav-1) is a small 22 kDa highly versatile pro-
tein capable of organizing several caveolar functions. Lisanti
and coworkers have precisely mapped the molecule defining
two sites involved in the binding of caveolar constituents: a
hydrophobic region (aa 82–101) called scaffolding domain
(SD), and amore hydrophilic motif present in the C-terminal
region indicated as CID motif [5].
Cellular prion protein (PrPc) is a secreted protein an-
chored to cell surface via a GPI anchor and believed to func-
tion as a cell surface receptor [6] or ligand [7, 8]. PrPc is char-
acterized by an amino terminal unstructured highly flexible
region characterized by the presence of multiple octapeptide
repeats highly conserved during evolution that are bind-
ing sites for copper ions [9]. In neuroblastoma cells lacking
caveolae, PrPc has been isolated in detergent-insoluble com-
plexes denominated “caveolae-like domains” (CLDs) and it
has been hypothesized that PrPc conversion in its patholog-
ical conformer PrP scrapie (PrPsc) occurs in this subcellu-
lar compartment [10, 11]. Recent data obtained by electron
microscopy in CHO cells clearly confirmed that PrPc is in-
ternalized by caveolae [12]. Moreover, it has been observed
that Cav-1 is coimmunoprecipitated by using PrPc antibody
and that Cav-1 mediates the recruitment and the activation
of Fyn kinase after anti-PrPc antibody-mediated stimulation
[13, 14]. Evidence supporting a role of PrPc in regulating cell
proliferation, differentiation, and survival has been collected
[15].
Fyn kinase is a member of Src family kinase involved in
signal transduction events. It has been reported that Fyn ki-
nase during signal transduction events is noncovalently as-
sociated with glycosylphosphatidylinositol (GPI)-anchored
proteins [16–18] and that Fyn kinase, after the palmitoyla-
tion of its Cys3, is included in caveolae [19]. Moreover, it has
been shown that, following antibody-mediated cross linking,
GPI-anchored proteins lead to signal transduction events in
T cells, B cells, monocytes, and granulocytes [20] and that
are sequestered in caveolae [21].
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Erk 1/2 has been intensively studied in neurons because
of its participation to hippocampal mechanisms leading to
learning and memory consolidation [22]. Caveolae play an
important role in Erk 1/2 regulation. In fact, it has been re-
ported that Erk 1/2 is compartmentalized within caveolae
[23, 24] and that Cav-1 can inhibit Erk 1/2 activity [25–29].
Interestingly, it has been reported that a reciprocal relation-
ship between Cav-1 and Erk 1/2 as activation of the p42/44
MAP kinase cascade causes the downregulation of Cav-1 ex-
pression [30].Moreover, the role of PrPc in Erk 1/2 activation
has been analyzed [14, 31, 32].
Findings reported here demonstrate that PrPc and Cav-1
interact in vitro and colocalize in GN11 cells, a hypothalamic
neuronal cell line that highly expresses Cav-1 gene.Moreover,
we examined the role played by caveolae and PrPc in signal
transduction by transfecting GN11 cells with a novel PrPc-
expressing vector showing a high transfection efficiency, in
order to compare Fyn and Erk 1/2 kinases activity in wild-
type and PrPc-overexpressing cells. Our results highlight the
key role of caveolae as sophisticated microenvironments in
which PrPc clusters to generate signal transduction pathways.
MATERIAL AND METHODS
Antibodies used
Anti-PrPc monoclonal antibody (Mab) 3F4 (western Blot
(WB) 1 : 3000; Immunofluorescence (IF) 1 : 50; DakoCy-
tomation, Denmark); antimurine PrP-N terminus polyclonal
antiserum Ab · Tg (kindly provided by Dr T. Yokoyama,
Japan [33]), anti-human PrP-C terminus goat polyclonal an-
tibody (Pab) C-20 (Santa Cruz Biotechnology, USA); anti-
human recombinant Doppel protein (hurDpl) Pab Q55 (WB
1 : 100); Mab Dpl 79 (kindly provided by Dr J. Grassi, Com-
missariat a l’Energie Atomique/Saclay, France); anti-Cav-1
Pab (WB 1 : 5000; IF 1 : 100; BD Biosciences, USA), anti-
Cav-1 FITC-conjugated antibody (IF 1 : 50; Santa Cruz
Biotechnology, USA), antihaemagglutinin (HA)-epitope Pab
(BD Biosciences, USA); anti-Fyn kinase Pab (IF 1 : 100;
Santa Cruz Biotechnology, USA), anti-phospho-Src family
(Tyr416) Pab (IF 1 : 200; Cell Signaling, USA), anti-phospho
Erk1/2 Mab (WB 1 : 1000; Cell Signaling, USA); anti-˜β-
actin Pab (WB 1 : 1200; Sigma, USA), secondary anti-mouse
FITC- or Cy3-conjugated antibodies (IF 1 : 50, Sigma, USA);
anti-rabbit Cy5-conjugated donkey Ab F(ab’)2 fragment (IF
1 : 50, Jackson, USA); anti-mouse and anti-rabbit secondary
Horseradish Peroxidase (HRP)-conjugated antibodies (WB
1 : 1000, Santa Cruz Biotechnology, USA). Antibodies were
diluted in PBS-BSA 3% or in 5% nonfat milk powder-TBS-
TWEEN buffer, for IF or WB experiments, respectively. For
live cells stimulation the antibodies were used at the dilution
of 1 : 100 in DMEM supplemented with 10% FCS.
Plasmid construction
Haemagglutinin-tagged PrP (PrP-HA) plasmid was prepared
as follows: the coding region (23–254) of mouse PrPc was
prepared, as described in Negro et al [34], with two Mets
at positions 108 and 111 (L108M, V111M) to provide the
epitope specific for commercial Mab 3F4. Then, the cod-
ing region was cloned into the mammalian expression vec-
tor pRK7HA (a kind gift of Dr Elisabetta Ciani, Bologna,
Italy), downstream of the HA-tag sequence, between BamHI
and EcoRI restriction sites. The region coding for mouse PrP
signal peptide (1–22) was then cloned into the recombinant
vector, upstream of the HA epitope sequence, between AgeI
and HindIII restriction sites. Expression vector for human
Dpl was prepared as in [34].
GST-binding assay
Recombinant full-length forms ofmorPrP (23–231) and hur-
Dpl (28–152) were generated in, and purified from, Es-
cherichia coli as described in Negro et al [34]. To provide the
epitope specific forMab 3F4, morPrP carried twoMets at po-
sitions 108 and 111 (L108M, V111M). Murine Cav-1 forms
were recombinantly obtained as GST-fusion proteins as de-
scribed in [35]. For binding assays, 0.2 μM of Glutathione S-
Transferase (GST) or GST-Cav fusion proteins (prebound to
glutathione-Sepharose beads) were incubated overnight with
equimolar amounts of morPrP or hurDpl (in a final vol-
ume of 0.25ml), under continuous shaking at 4◦C. Proteins
bound to glutathione-Sepharose beads were eluted, washed,
and immunoblotted to detect the presence of PrP or Dpl.
In competition experiments, equimolar amounts of either
Ab · Tg or C-20 antibodies were present during the entire in-
cubation period.
Determination of the dissociation constant for
the binding GST-Cav fusion proteins and morPrP
Different concentrations of morPrP (0.03–0.7 μM) were in-
cubated with 0.2 μMGST-Cav fusion proteins (GST-Cav 61–
101, GST-Cav 135–178, and GST-Cav FL 1–178) in the same
conditions described above. Proteins bound to glutathione-
Sepharose beads were eluted and exposed to western blot-
ting assay. The blots, stained with anti-PrP Mab 3F4, were
analyzed in transmitted light by ImageMaster VDS software
(Pharmacia Biotech, Sweden) to measure the intensity of the
bands. PrP concentration was plotted as a function of band
intensity expressed in arbitrary units.
Western blot
For western blot analysis, denatured proteins were first sep-
arated by a 12% SDS-PAGE, electrophoretically transferred
onto nitrocellulose and then, depending on the experiment,
incubated with the specific antibodies. Immunolabeling was
visualized by ECL procedure (Amersham, UK) and the band
intensities were measured by ImageMaster VDS software
(Pharmacia Biotech, Sweden).
Cell culture and transfection
Murine GN11 cells [36] were grown at 37◦C in 5% CO2 at-
mosphere in high glucose-culture medium (DMEM, Sigma,
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USA), supplemented with 10% heat-inactivated fetal calf
serum (FCS, Cambrex BioWhittaker, USA), 2mM L-gluta-
mine, penicillin (100U/ml), and streptomycin (100 μg/ml),
as described in [37].
Cells were transiently transfected by using Lipofec-
tamine 2000 reagent (Invitrogen, USA), following manufac-
turer’s instructions. For cell differentiation, phorbol ester 12-
O-tetradecanoylphorbol-13-acetate (TPA) (20 nM, Sigma,
USA) was added to cells soon after the transfection step, de-
pending on the experiment. For Western blot experiments,
cells were trypsinized 24 hours after transfection and re-
seeded in 25 cm2 flasks to obtain the same number of trans-
fected cells in each flask. To assess the Erk 1/2 phospho-
rylation status, cells were serum-starved for 4 hours before
antibody-mediated ligation of PrPc. Depending on the ex-
periments, 30 μM PP2 (Calbiochem, USA) was added to
the medium for 4 hours. In both immunoblotting and im-
munocytochemistry experiments, 48 hours after transfec-
tion, antibody-mediated stimulation was carried out first by
incubating (10, 20, or 30min, 37◦C) intact live cells withMab
3F4, Mab Dpl 79, or anti-˜β-actin Pab and then with sec-
ondary anti-mouse or anti-rabbit antibodies for additional
10–120min. (37◦C), depending on the experiment. Then,
cells were lyzed in lysis buffer (50mM Tris-HCL, pH 7.5,
2mM EDTA, 100mM NaCl, 1% Triton X100, 5mM NaF,
1mM Na3VO4, 10mM β-glycerolphosphate, and proteases
inhibitors) or fixed with 4% paraformaldehyde, for western
blot or immunofluorescence analysis, respectively.
Immunocytochemistry
PrPc-overexpressing GN11 cells grown on coverslips were
fixed with 4% paraformaldehyde and incubated with Mab
3F4 or were stimulated by antibody-mediated ligation and
fixed. Cells were permeabilized with Triton X-100 (0.1% in
phosphate buffer saline (PBS)) and saturated in PBS-BSA
3% for 30min. Then, cells were incubated with anti-Cav-
1 or anti-phospho Fyn Pabs (for double fluorescence stain-
ing experiments) or with anti-Fyn kinase Pab (for triple flu-
orescence staining experiments). After washings, cells were
incubated with anti-mouse FITC-conjugated and with anti-
rabbit Cy5- (for double staining) or Cy3- (for triple staining)
conjugated secondary antibodies. For triple immunofluores-
cence staining experiments, anti-Cav-1 FITC-conjugated an-
tibody was added. Finally, slides were mounted in glycerol-
PBS medium containing 30mg/ml DABCO (Sigma, USA).
Evaluation of antibody specificity was carried out either by
omitting primary antibody or by using unspecific sera.
Confocal microscopy
The confocal imaging was performed on a Radiance 2000
confocal laser scanning microscope (BioRad), equipped with
a Nikon 40x, 1.4 NA objective, and with a Krypton and a Red
Diode lasers, to excite FITC (green) and Cy5 (red) fluores-
cence simultaneously. Colocalization was evaluated on me-
dial optical sections using LaserPix software (BioRad) [38].
Briefly, the two-dimensional scatter plot diagram of each
cell was analyzed to evaluate the spatial colocalization of the
fluorochromes. For each scatter plot diagram, pixels with
highly colocalized fluorochromes, that is, with intensity val-
ues greater than 150 gray levels (on a scale from 0 to 255) for
both detectors were selected to calculate the colocalization
maps and create a binary image.
Optiprep gradient flotation
Optiprep density gradient flotation was performed as de-
scribed in Harder et al [39]. Briefly, PrPc-overexpressing
TPA-differentiated cells (one confluent 25 cm2 flask) were
lyzed (20min, 4◦C) in 200 μl of a TNE/TX buffer (25mM
Tris HCl (pH 7.4), 150mM NaCl, 5mM EDTA, 5mM DTT,
1% Triton X-100, and protease inhibitors), mixed with 400 μl
of 60% Optiprep reagent (Sigma, USA), placed at the bot-
tom of an ultracentrifuge tube, and overlaid with a 600 μl
step of each of 35%, 30%, 25%, 20%, and 0% Optiprep (in
TNE/TX). The gradient was spun at 200.000 xg (4 hours,
4◦C), after which fractions were collected from the top of the
gradient, acid-precipitated, and analyzed by western blot.
Coimmunoprecipitation assay
In Cav-1 immunoprecipitation experiments, cells transiently
expressing the HA-tagged PrPc (one confluent 25 cm2 flask
for each sample) were lyzed in 500 μl of a buffer con-
taining 10mM Tris (pH 7.5), 150mM NaCl, 1mM EDTA,
1% Triton X-100, 0.5% NP40, 10% glycerol, and protease
inhibitors. Precleared supernatants were immunoprecipi-
tated using anti-Cav-l Pab (3 μg/ml), followed by incubation
with protein A Sepharose [35]. After washings, immuno-
precipitated samples were processed by western blot to de-
tect PrPc. For sample deglycosylation, immunoprecipitates
were treated (24 hours, 37◦C) with PNGase-F (5U) (Roche
Molecular Biochemicals, Germany) [40]. For PrP immuno-
precipitation, the same protocol described above was fol-
lowed, except for the use of an anti-HA tag antibody to im-
munoprecipitate. The presence of Cav-1 in the immunopre-
cipitated samples was then assayed by immunoblotting with
anti Cav-1 Pab.
RESULTS AND DISCUSSION
Interaction between PrP and Cav-1
To evaluate the interaction between Cav-1 and PrPc, we
carried out in vitro binding experiments as previously de-
scribed in [35], by using four different GST-Cav1 fusion pro-
teins and a control GST-nonfusion protein to challenge mor-
PrP. Bound PrP molecules were then immunodetected by
western blot analysis. Results clearly show that GST-CavFL
(full lenght, aa 1–178), GST-CavSD (scaffolding domain, aa
61–101), and GST-CavCT (C-terminal region, aa 135–178)
very efficiently bind morPrP. No morPrP was bound when
GST alone and GST-CavNT (N-terminal region, aa 1–81)
were challenged, indicating that the binding was specific
(Figure 1(a), 1).
We hypothesized that the unstructured PrP N-terminal
region [41] could represent an important binding site for
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Figure 1: (a) In vitro interaction between Cav-1 and morPrP. To assess the binding of morPrP (23–231) and hurDpl (28–152) to different Cav-
1 domains (CavFL: full-length form (1–178); CavNT: N-terminal domain (1–81); CavSD: scaffolding domain (61–101); CavCT: C-terminal
domain (135–178)), prion proteins were incubated with equimolar amounts (0.2 μM) of GST-Cav fusions bound to glutathione-Sepharose
beads. BoundmorPrP (1, 3) and hurDpl (2) were then visualized by western blotting withMab 3F4 and polyclonal antibodyQ55, respectively.
In 3, the binding assay was carried out in the presence of polyclonal antibodies (0.2 μM) to PrP, namely, Ab · Tg recognizing the octapeptide
region, and C-20 directed against the C-terminus. In the first lane of (a) 1, 2, 3, 50 ng morPrP or hurDpl were added as standard, while in
the second lane of (1) and (2) GST alone (ie, not fused to Cav-1) was used for the binding experiments as negative control. Data shown
are representative of three independent experiments. (b) Evaluation of Kd values of morPrP/Cav-1 complexes. Increasing concentrations of
morPrP (0.03–0.7 μM)were incubated with GST-Cav 1 fusion proteins: CavFL in 1, CavSD in 2, and CavCT in 3, as described underMaterials
and Methods. The upper parts of (b) 1, 2, 3 show the results of western blotting experiments performed with anti-PrPc antibody (3F4). Lane
1, morPrP used as standard; lanes 2–7, 50 pmoles of GST-Cav 1 fusion proteins, CavFL in 1, CavSD in 2, and CavCT in 3, were incubated
with the indicated amounts of morPrP (final volume 250 μl). In lower parts of each panel, the concentration of morPrP used in binding
assays was plotted as a function of band intensity, which was quantified using ImageMaster VDS Software (Pharmacia Biotech, Sweden). The
dissociation constants calculated from each plot ranged from 8 to 9 ×108 M−1. The data are representative of two independent experiments.
Cav-1. This region is characterized by the presence of an
octapeptide sequence PHGGGWGQ repeated five times in
tandem and involved in the binding of copper ions [9]. To
demonstrate our hypothesis, we first evaluated whether Dpl
protein binds to Cav-1. Dpl is a protein which shows high
sequence homology with the C-terminus of PrPc but lacks
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the N-terminal octapeptide region [42, 43]. To this end, we
probed the hurDpl under the same conditions used for mor-
PrP binding to Cav-1. However, contrary to morPrP, hurDpl
showed no interaction with Cav-1 (Figure 1(a), 2).
More details about the PrPc N-terminal sites involved in
the binding to Cav-1 were obtained using a polyclonal anti-
body Ab · Tg. This antibody specifically recognized two non-
adjacent octapeptide repeats (57–65 and 81–89) since a sub-
stitution G/S was sufficient to abrogate recognition. The use
of Ab · Tg antibody almost completely blocked the morPrP
binding to GST-Cav SD (61–101), while an antibody directed
against a PrP C-terminal epitope had a much lower effect
(Figure 1(a), 3). Taken together, these results indicate that
the octapeptide repeats could represent a PrP binding site for
Cav-1.
The results of experiments aimed at evaluating the
PrP/Cav-1 binding affinity constants are shown in Fig-
ure 1(b). Amounts of morPrP ranging from 0.03 μM to
0.7 μM were incubated with different GST-caveolin fusion
proteins, as described under Material and Methods. Bands
intensity in western blots was quantified by densitometry.
Plots representing the binding of GST-CavFL (1–178), GST-
CavSD (61–101), and GST-CavCT (135–178) are shown in
panels B1, B2, and B3, respectively. Evaluation of dissocia-
tion constant (Kd) by reciprocal plots showed that Kd ranged
from 8 to 9 ×108 M−1 for all the three fusion proteins. Since
no binding was observed using GST alone or GST CavNT
fusion protein, it appears that unspecific binding is not oc-
curring in our experimental conditions.
To determine if the interaction between PrP and Cav-1
observed in vitro occurred also in a physiological environ-
ment and if this interaction had any effects on signal trans-
duction, we used, as cellular model, a cell line of immortal-
ized luteinizing hormone-releasing hormone (LHRH) neu-
rons that naturally expresses high levels of Cav-1 [44] and
that was prone to be transiently transfected with high ef-
ficiency with a plasmid encoding the HA tagged morPrP
protein.
In PrPc-overexpressing GN11 cells, PrPc appears uni-
formly distributed on the plasma membrane (Figure 2(a), 1)
and shows a low colocalization level with Cav-1 (Figure 2(a),
3 and 4). Given that it has been shown that GPI-anchored
proteins residing in rafts translocate to caveolae following
clustering induced by antibody-mediated cross-linki [21,
39], we stimulated live PrPc-overexpressing GN11 cells with
anti-PrPc antibody (30min) and with FITC-conjugated sec-
ondary antibody (30min), observing that PrPc clusters in
plasma membrane microdomains (in Figure 2(a), 5 and 9,
arrowheads indicate the clusters of PrPc) rich in Cav-1
(Figure 2(a), 6 and 10). In these clusters we detected a high
level of colocalization between PrPc and Cav-1 (Figure 2(a),
8 and 12).
In order to obtain a neuronal environment closer to that
in which PrPc operates physiologically, we treated GN11 cells
with TPA, an inducer of cell differentiation (Figure 2(b), 1–
4). Analysis of PrPc-overexpressing GN11 cells treated with
TPA has shown an increase in the co-localization level be-
tween PrPc and Cav-1 (Figure 2(b), 3 and 4). Since in vitro
experiments (Figure 1(a), 2) have shown an incapacity of
Cav-1 to bind Dpl and since Dpl is a surface protein ex-
posed to the exoplasmic space through a GPI-anchor like
PrPc [45], confocal microscopy analyses were performed on
GN11 cells overexpressing the Dpl protein differentiated with
TPA (Figure 2(b), 5–8). When Dpl was cross-linked using a
specific antibody, colocalization with Cav-1 at plasma mem-
brane level was undetectable (Figure 2(b), 7–8) confirming a
different behavior between PrPc and Dpl and suggesting that
Doppel, although located through a GPI anchor in the same
microdomains of PrPc, could be unable to participate in
the transduction of survival signals, thus favoring conditions
slowly leading to apoptosis. For example, failure of Doppel to
bind Cav-1 could impair Fyn kinase recruitment due to PrPc
activation [13], thus altering the normal fate of cell differ-
entiation occurring during brain development. Our results
may also help to explain why the reintroduction of a wild-
type Prnp gene, in PrPc 0/0 mice expressing Doppel protein
in the brain, rescues them from neurodegeneration [46]. In
fact, PrPc, having a higher affinity for transducing machin-
ery, may displace Doppel protein and trigger survival signals.
Evidence supporting a role of PrPc in regulating cell prolifer-
ation, differentiation, and survival has been recently collected
by Satoh and coworkers [47], who compared the gene expres-
sion profile in fibroblast cell lines derived from PrPc-deficient
mice (Prnp 0/0) and from PrP wild-typemice. They observed
that the disruption of Prnp gene resulted in an aberrant reg-
ulation of a battery of genes important for cell proliferation,
differentiation, and survival, including those located in the
Ras and Rac signaling pathways. Moreover, Kuwahara and
coworkers [48] observed that the reintroduction of wild-type
Prnp gene prevented apoptosis in hippocampal cells derived
from Prnp 0/0 mice and cultured under serum-free condi-
tions.
To further confirm the PrPc/Cav-1 colocalization, ex-
periments of flotation in density gradient were performed.
Extracting cells with Triton X-100 at 4◦C and fractionat-
ing the insoluble material by OptiPrep or sucrose-gradient
centrifugation are considered a stringent criterion to es-
tablish whether a protein is present in detergent-insoluble
glycolipid-rich domains (DIGs) and colocalizes with Cav-1
[49]. Nevertheless, it is difficult to obtain a separation be-
tween rafts and caveolae. We applied this procedure to GN11
cells, transiently transfected with Prnp or Prnd, and eval-
uated PrPc, Cav-1, and Dpl distribution by western blot.
Results obtained (Figure 3(a)) show a marked colocaliza-
tion between PrPc and Cav-1 in low-density gradient frac-
tions (Figure 3(a), 1 and 2, resp.). Interestingly, Dpl protein
(Figure 3(a), 3), even if it is a GPI-linked protein too, shows a
wide distribution in most fractions of the gradient that does
not correlate with Cav-1 distribution.
Mouillet-Richard et al [13] detected the presence of Cav-
1 in immunoprecipitated samples obtained by using an anti-
PrPc antibody, particularly when neuronal cells were in-
duced to differentiate. We proposed to confirm these re-
sults in GN11 neuronal cells transiently transfected with
murine Prnpgene. Reciprocal coimmunoprecipitation ex-
periments in HA tagged-PrPc-overexpressing GN11 cells
6 Journal of Biomedicine and Biotechnology
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Figure 2: Confocal microscopy analysis of PrPc, Dpl, and Cav-1 distribution in GN11 cells transfected with morPrP or hurDpl. (a) PrPc-
overexpressing GN11 cells were fixed (1–4) and incubated with anti-PrP Mab 3F4 and with secondary FITC-conjugated antibody to allow
the visualization of PrPc on the plasma membrane of unstimulated cells (1). Then cells were permeabilized and incubated with anti-Cav-
1 Pab to visualize Cav-1 distribution (2). Live GN11 cells PrPc transiently transfected were incubated with anti-PrP Mab 3F4 (30min),
followed by secondary FITC-conjugated antibody (30min) (5–8, corresponding to 9–12 after magnification) to allow antibody-mediated
ligation (and visualization) of PrPc (5), (9). After fixing, cells were permeabilized and incubated with anti-Cav-1 Pab and secondary CY5-
conjugated antibody to visualize Cav-1 distribution ((6), (10)). Superposition of green PrPc ((1), (5), and (9)) and cyan-blue Cav-1 ((2),
(6), and (10)) signals provided the images shown in 3, 7, and 11. The binary maps presented in 4, 8, and 12 are a more precise means
to evaluate colocalization, whereby only those regions, in which PrPc and Cav-1 are copresent above a defined threshold of fluorescence
intensity, appear. Micrographs show a single confocal plane. Arrowheads indicate PrPc clusters where Cav-1 is also present. Bar = 40 μm. (b)
The same protocol used to analyze PrPc and Cav-1 distribution in GN11 cells in (a) was applied to GN11 cells stimulated by TPA (20 nM,
48 h) (1–4). Note that TPA treatment increases surface colocalization of PrPc (green) and Cav-1 (red) ((3), (4)). When the same methods
were used to analyze the distribution of Dpl (green) and Cav-1 (red) in Dpl-transfected cells activated by anti-DplMab 79 antibody (5–8), no
evident proteins colocalization was found ((7), (8)). For other experimental details see Material andMethods. Images result from integrating
different optical sections. Bar = 5 μm.
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Figure 3: (a) Optiprep density gradient flotation of PrPc, Dpl, and Cav-1 proteins from GN11 cell lysates. Differentiated (TPA-treated) GN11
cells, transiently transfected with morPrP or hurDpl, were lyzed in 1% Triton X-100 at 4◦C and subjected to flotation on discontinuous
Optiprep gradient (0–40%). Gradient fractions were collected and examined by immunoblotting with anti-PrP (1), anti-Cav-1 (2), and anti-
Dpl (3) antibodies. Optiprep concentration in each fraction is indicated above each lane. The data are representative of three independent
experiments. Bar = 40 μm. (b) PrP and Cav-1 coimmunoprecipitation assay. Live GN11 cells transfected with HA tagged-PrP plasmid were
untreated (lane 1) or activated by anti-PrP antibody-mediated ligation (lanes 2–4). Cell lysates were collected and immunoprecipitated
with either anti-HA (lanes 1 and 2) or anti-Cav-1 (lanes 3 and 4) antibodies. The immunoprecipitates were immunoblotted and blots were
incubated with anti-Cav-1 (lanes 1 and 2) or anti-PrP antibodies (lanes 3 and 4), respectively. In lane 2, anti-Cav-1 antibody detects a band
of the apparent molecular weight of 22 kDa typical of Cav-1. Anti-PrP antibody reveals the presence of bands with apparent mass typical of
PrPc glycoforms (lane 3). When cell immunoprecipitate was subjected to deglycosylation by PNGase-F, a unique band (at 27 kDa), having
the expected electrophoretic mobility of unglycosylated PrPc, appeared (lane 4). Data are representative of two independent experiments
.
were performed to further confirm PrPc-Cav1 interac-
tion (Figure 3(b)). We found that anti-HA-tag antibodies
coimmunoprecipitate Cav-1 (Figure 3(b), lane 2) and, re-
ciprocally, that anti-Cav-1 antibodies coimmunoprecipitate
PrP (Figure 3(b), lanes 3 and 4) in cells stimulated by
anti-PrPc antibody- (30min) and by secondary antibody-
(30min) mediated ligation. After deglycosylation treatment
(Figure 3(b), lane 4), the smear typical of PrPc was resolved
in a single band of 27 kDa. Interestingly, the sensitivity of
western blot detection did not permit to reveal Cav-1 in
coimmunoprecipitates of unstimulated cells (lane 1) con-
firming the importance of antibody stimulation in PrPc/Cav-
1 interaction.
To follow the fate of PrPc/Cav-1 complexes, a time-
course of PrPc and Cav-1 distributions after anti-PrPc
antibody-mediated stimulation was analyzed by confocal
microscopy in living GN11 cells overexpressing PrPc. In
Figure 4 it is shown that the PrPc/Cav-1 colocalized sig-
nal, at plasma membrane level, was evident after 60min of
anti-PrPc antibody-mediated stimulation (A–D). However,
after 90min, PrPc was prominent in the intracellular space
and only a few spots of colocalized signals were present at
plasma membrane level (E–H). After 150min, PrPc became
almost exclusively intracellular (I) while Cav-1 distribution
appeared unchanged (J), and colocalization signals were un-
detectable (K), (L). It is likely that when caveolae are de-
tached from surface membrane the dissociation of PrPc/Cav-
1 complexes takes place. However, western blotting analysis
of PrPc at different times (M, N, and O) showed that no
degradation of PrPc, even after 2 h, was evident. Moreover,
the extent of PrPc glycosylation was unchanged.
Involvement of PrPc in signal transduction
Since we hypothesized a role of PrPc clustering and of PrPc-
Cv 1 colocalization in signal transduction, we performed
confocal microscopy experiments to assess if Fyn kinase re-
sponds, in someway, to an anti-PrP antibody-mediated stim-
ulation (Figure 4). Biedi and collaborators demonstrated
the recruitment of Fyn kinase from cytoplasm to caveo-
lae in fibroblasts overexpressing wild-type IGF-IR stimu-
lated by IGF-I [50]. In a similar way, after the stimula-
tion of PrPc-overexpressing GN11 cells with anti-PrPc an-
tibody (30min) and with secondary antibody (30min) to
induce PrPc patching, we observed the shift of Fyn kinase
from the cytoplasm towards the membrane (in Figure 5(c),
compare the Fyn distribution in a transfected cell sub-
jected to the stimulation (arrowhead) with an untrans-
fected cell not subjected to the stimulation (arrow)). Af-
ter the antibody-mediated stimulation, we revealed a high
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Figure 4: Time course of antibody-mediated PrPc internalization. As detailed above (Figure 2), the anti-PrPc antibody-mediated stimulation
was achieved by incubating live GN11 cells withMab 3F4 for 30min, followed by FITC-conjugated secondary antibody, for a total incubation
time of either 60min (A–D), (M), 90min (E–H), (N), or 150min (I–L), (O). After fixing and permeabilizing, cells were probed with anti-
Cav-1 Pab and Cy5-conjugated anti-rabbit secondary antibody. The distribution of PrPc (A, E, and I) and Cav-1 (B, F, and J) at the different
incubation periods, the superposition (C, G, and K) of the green (PrPc) and red (Cav-1) signals, and the corresponding binary maps (D,
H, and L) are shown. Note that after 150min, the major internalization of PrPc is quite independent from Cav-1 movements (I–L). Panels
M–O represent western blot (WB) analysis of cell lysates for the presence of PrPc glycoforms under the different conditions described. On
the right margin, standard molecular weights are reported. For further experimental details see Material and Methods. Bar = 7.5 μm.
colocalization between PrP and Cav-1 (panel D) and be-
tween PrP and Fyn kinase (panel E) on the plasma mem-
brane. It was previously reported that PrPc and Fyn ki-
nase do not colocalize in neurons; however in those ex-
periments cells were not stimulated by anti-PrPc antibody
[51].
To evaluate if the Fyn kinase recruited in the clusters
of PrPc/Cav-1 was activated, we performed confocal im-
munofluorescence experiments by using a specific antibody
that recognizes the active form of Fyn kinase phosphory-
lated on Tyr 416 (Figure 6). In GN11 cells that do not ex-
press PrPc, the signal of active Fyn kinase is low and wide
dispersed in the cytoplasm (data not shown). On the con-
trary, in PrP-overexpressing GN11 cells we detected a low
activation of Fyn kinase on plasma membrane (Figure 6, B
and F). Following anti-PrPc antibody-mediated stimulation
(20min), an increased level of active Fyn kinase located in
the correspondence of PrPc clusters was detected (J, N, ar-
rowheads indicate PrPc clusters). After 40min of antibody
stimulation, the signal of active Fyn kinase was weaker and
after 60min it was no more detectable (data not shown).
Taken together, these data show that following anti-PrPc an-
tibody mediated stimulation, PrPc patches on the plasma
membrane in clusters in which Fyn kinase is recruited and
activated.
It has been reported that activated Fyn kinase can trans-
duce a signal cascade through Erk 1/2 kinase [52]. To evaluate
if in GN11 cells the activation of PrPc by antibody-mediated
ligation triggers a signal transduction pathway through Erk
1/2, we perform the experiments reported in Figure 7. The
incubation of PrP-overexpressing GN11 cells with anti-PrPc
(3F4) and secondary antibody for a total time of 20 and
40min caused the activation of Erk 1/2 kinase by induc-
ing their phosphorylation (lanes 3 and 4), while the incuba-
tion with unrelated antibodies had no effects (lane 5). Erk1/2
phosphorylation levels did not increase if cells were previ-
ously treated with the Fyn kinase inhibitor PP2 (lane 6). This
result suggests that the activation of Fyn kinase following
anti-PrPc antibody-mediated stimulation, observed by con-
focal microscopy, may trigger a downstream activation of
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Figure 5: Fyn kinase shift from cytoplasm into membrane caveolae. Live GN11 cells PrPc transiently transfected were incubated with anti-
PrP Mab 3F4 (30min), followed by secondary Cy3-conjugated antibody (30min), to allow antibody-mediated ligation (and visualization)
of PrPc B. After fixing and permeabilizing cells, anti-Fyn kinase polyclonal antibody and secondary Cy5-conjugated antibody were added
to visualize Fyn kinase distribution (C). Finally, anti-caveolin1 FITC-conjugated antibody was added to visualize Cav-1 distribution (A).
The superposition of green (Cav-1 in D; Fyn kinase in E) and red (PrPc in D and E) signals provided the images shown in D and E.
Arrowheads show the PrPc-overexpressing cells and arrows do not indicate transfected cells. Images (A–E) result from integrating different
optical sections.. Bar = 7.5 μm.
Erk 1/2 signaling pathway. Our data, obtained in a neuronal
model expressing Cav-1, confirm that PrPc triggers a Fyn ki-
nase and Erk 1/2 signaling pathway as previously reported
[15, 31, 32, 53].
To obtain this activation, PrPc and Fyn kinase need to
co-localize in caveolae: PrPc clusters on the plasma mem-
brane following the antibody (or other putative physiolog-
ical ligands) binding, and Fyn kinase moves from cytoplasm
to caveolae.
In order to demonstrate the essential role of Cav-1 in
the PrPc-Fyn-Erk 1/2 signaling pathway, we down-regulated
or misallocated caveolin 1 by using anti-Cav-1 antisense
oligonucleotides and Filipin III, respectively. The aim was to
obtain an experimental condition in which the absence of
Cav-1 could prevent the activation of the transduction cas-
cade triggered by PrPc clustering. However, these treatments
in GN11 cells did not permit to obtain clear results as they
caused a strong increase of Erk 1/2 phosphorylation level
(data not shown). The ability of Cav-1 to directly inhibits Erk
1/2 activation has been reported in other experimental mod-
els [25, 26]. Moreover, the hyperactivation of Erk 1/2 signal-
ing was reported in Cav-1 (−/−) null mouse cells and tissues
[28, 29, 54], and in NIH-3T3 cells in which Cav-1 was down-
regulated by antisense [27]. The inhibitory effect of Cav-1 on
Erk 1/2may explain why, in our cellularmodel, it is so hard to
demonstrate the direct involvement of Cav-1 in signal trans-
duction events triggered by PrPc stimulation.
The data reported here confirm the involvement of PrPc
in signal transduction events through Fyn and Erk 1/2 ki-
nase and demonstrate caveolae to be the physical place
in which this signal cascade switches on. In vitro binding
experiments’s results suggest that a physical interaction be-
tween PrPc and Cav-1 could be involved in these signaling
events, even if this is unlikely considering the nowadays-
accepted location of PrPc and Cav-1 on the opposite side of
the plasma membrane.
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Figure 6: Fyn kinase is activated in PrPc/Cav-1 clusters on plasma membrane. PrPc-overexpressing GN11 cells were fixed and incubated
with anti-PrP Mab 3F4 and with secondary FITC-conjugated antibody to allow PrPc visualization (A, E). Live GN11 cells PrPc tran-
siently transfected were incubated with 3F4 Mab (30min), followed by secondary FITC-conjugated antibody (30min) (I–P), to allow
antibody-mediated ligation (and visualization) of PrPc (I, M). After fixing, cells were permeabilized and incubated with anti-phospho
Fyn kinase (Tyr 416) Pab and secondary Cy5-conjugated antibody to visualize the distribution of active Fyn kinase (B, F, J, and N). Su-
perposition of the green PrPc (A, I corresponding to E, M after magnification) and red phospho Fyn (B, J corresponding to F, N after
magnification) signals provided the images shown in C, G, K, O. The binary maps presented in D, H, L, P are a more precise means to
evaluate colocalization, whereby only those regions, in which PrPc and phospho Fyn are copresent above a defined threshold of fluores-
cence intensity, appear. Arrowheads show the PrPc clusters on the plasma membrane. Micrographs show a single confocal plane. Bar =
40 μm.
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Figure 7: Erk 1/2 phosphorylation in GN11 cells stimulated with anti-
PrPc antibody. GN11 cells were transfected with empty HA-plasmid
Prk7HA (lane 1) or PrP-HA plasmid (lanes 2–7) and incubated with
anti-PrP-antibody (3F4) for 20 (lane 3) and 40 (lanes 4 and 7) min.
In lane 5, cells were incubated with an unspecific antibody (anti-β-
actin) for 40min. In lanes 6 and 7, cells were treated with the Fyn
kinase inhibitor PP2 (30 μm, 4 h). Cell lysates were collected and
analyzed by western blot using anti-phospho-p44/42 MAP kinase
antibody (a) and anti-β-actin antibody (b). Band intensities were
evaluated by ImageMaster software (Pharmacia Biotech, Sweden).
In (c), we reported the intensity values of the bands corresponding
to phosphorylated Erk 1 and Erk 2 (black and white bars, resp.)
normalized with respect to β-actin band intensity values. Data are
representative of three independent experiments.
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